Loading events...
Elixir Medical’s DynamX bioadaptor has been shown to diminish target lesion failure (TLF) by 48% in a landmark clinical trial. Elixir Medical’s coronary implant, DynamX bioadaptor, has been proven to significantly reduce the risk of device-related cardiac events compared with current-generation drug-eluting stents in a landmark clinical trial in coronary artery disease (CAD).
Monday, October 27, 2025
San Francisco, USA
Elixir Medical’s DynamX bioadaptor has been shown to diminish target lesion failure (TLF) by 48% in a landmark clinical trial. Elixir Medical’s coronary implant, DynamX bioadaptor, has been proven to significantly reduce the risk of device-related cardiac events compared with current-generation drug-eluting stents in a landmark clinical trial in coronary artery disease (CAD).
Receive curated event recommendations based on your interests.
See how WebMobi helps you manage registration, check-in, and analytics.
Request a DemoOr start free trial →TCT 2025: Elixir Medical’s arterial implant drops coronary events by nearly 50% takes place on Monday, October 27, 2025.
TCT 2025: Elixir Medical’s arterial implant drops coronary events by nearly 50% is held in San Francisco, USA.
Pricing information is available on the event website.
TCT 2025: Elixir Medical’s arterial implant drops coronary events by nearly 50% is designed for healthcare professionals looking to network, learn, and discover new opportunities.
Get curated B2B events, AI-powered insights, and industry trends delivered to your inbox